Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Oxford jab prompts immune response among old as well as young 

British&nbsp;drugmaker&nbsp;AstraZeneca said on Monday that one of the world&rsquo;s leading&nbsp;Covid-19&nbsp;vaccine candidates which is being developed by the University of Oxford,&nbsp;produces&nbsp;a&nbsp;immune response in both young and old adults. The development&nbsp;raises&nbsp;hopes&nbsp;of a path out of the gloom and economic destruction&nbsp;brought&nbsp;by the novel&nbsp;coronavirus.&nbsp;AstraZeneca said the&nbsp;Oxford&nbsp;vaccine&nbsp;candidate&nbsp;also triggers lower adverse responses among the elderly.&nbsp;A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people.&nbsp;

British&nbsp;drugmaker&nbsp;AstraZeneca said on Monday that one of the world&rsquo;s leading&nbsp;Covid-19&nbsp;vaccine candidates which is being developed by the University of Oxford,&nbsp;produces&nbsp;a&nbsp;immune response in both young and old adults. The development&nbsp;raises&nbsp;hopes&nbsp;of a path out of the gloom and economic destruction&nbsp;brought&nbsp;by the novel&nbsp;coronavirus.&nbsp;AstraZeneca said the&nbsp;Oxford&nbsp;vaccine&nbsp;candidate&nbsp;also triggers lower adverse responses among the elderly.&nbsp;A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people.&nbsp;

AstraZeneca, J&J Covid vaccine trials back on track in US

AstraZeneca Plc and Johnson &amp; Johnson to resume Covid-19 vaccine clinical trials that had been halted by US regulators.

2 vaccine candidates back on track in US
AstraZeneca&nbsp;&amp;&nbsp;J&amp;J to resume clinical trials
US suspended trial after participant fell ill: AstraZeneca
J&amp;J's statement: resume trial after consultating&nbsp;FDA
&nbsp;
&nbsp;

Two major clinical trials for experimental Covid-19 vaccines got back on track in the United States on Friday providing a glimmer of hope. AstraZeneca Plc and Johnson &amp; Johnson plan to resume Covid-19 vaccine clinical trials that had been halted by US regulators, putting research into two of the leading candidates for a coronavirus inoculation back on track. AstraZeneca announced that the trial of its vaccine candidate, developed with Britain's University of Oxford, has resumed in the US, the only country where it remained suspended following a participant's illness six weeks ago. While Johnson &amp; Johnson said in a statement that it is preparing to resume recruitment in a late-stage trial of its vaccine after consultation with the US Food and Drug Administration.&nbsp;

Serum Institute gets nod to resume Covid vaccine trials

Drugs Controller General of India on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate

Drugs Controller General of India on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate. The DCGI, Dr V G Somani, has however, put certain conditions like taking extra care during screening, providing additional information in informed consent to be followed during the trials. The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford Covid-19 vaccine in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of "an unexplained illness" in a volunteer.

New Delhi, PTI: Drugs Controller General of India (DCGI) Dr V G Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.
The DCGI, however, put certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which have to be "scrupulously" followed by Serum Institute of India (SII).
SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.
The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford Covid-19 vaccine candidate till further orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of ''an unexplained illness'' in a participant in the study.
On Saturday, British-Swedish biopharmaceutical giant AstraZeneca and the University of Oxford said clinical trials for their coronavirus vaccine have resumed in the UK after the Medicines Health Regulatory Authority's (MHRA) confirmed that the trials were safe.
SII, which has partnered with AstraZeneca for manufacturing the vaccine candidate for Covid-19, on Tuesday submitted the recommendations of the Data and Safety Monitoring Board (DSMB), UK and DSMB, India, and requested for permission to restart enrolment in the clinical trial.
According to Tuesday's order issued by DCGI, the DSMB, UK, recommended that the investigators recommence all immunization in their clinical trials subject to certain conditions.
DSMB, India, also has recommended to continue the study and enroll the remaining participants in the clinical trial as per protocol subject to certain conditions.
According to the order, SII has submitted revised participant information sheet, revised informed consent form and additional safety monitoring plan for the evolved participants.

Volunteer falls ill, Covid vaccine trial put on hold

Pharma giant AstraZeneca has paused a clinical trial of its coronavirus vaccine after a volunteer developed an unexplained illness. The company calls the hold routine

Pharma giant AstraZeneca has paused a clinical trial of its coronavirus vaccine after a volunteer developed an unexplained illness, the company said on Tuesday. AstraZeneca, which is developing the drug alongside the University of Oxford, is a frontrunner in the global race for a Covid-19 vaccine. The company said that the pause was a routine action which happen whenever there is a potentially unexplained illness in one of the trials. "It is investigated, ensuring we maintain the integrity of the trials," it said. It was not immediately clear where the patient was, or the nature and severity of their illness.

university of oxford

Categories